BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Related Posts
17Nov
PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial
Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a... read more
03Nov
Privo receives Orphan Designation from the Food and Drug Administration.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more
19Aug
Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting
PEABODY, Mass., June 3, 2021 -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more
14Oct
Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery
Privo Technologies, Inc. a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the... read more
02Dec
Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more
27Aug
Privo Technologies, Inc. Announces Publication in Nature Communications
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more
27Aug
Privo Technologies Receives $4.5M Funding from National Cancer Institute for Phase 3 Clinical Trial of Innovative Oral Cancer Treatment
Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support... read more
01Aug
Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
01Jan
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more
10Dec
Privo Technologies receives 2015 TechConnect Innovation Award
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more
- © UX Strategy & Digital Branding
